- Home
- RARE vs BTU Comparison
RARE vs BTU Comparison
Compare RARE & BTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- BTU
- Stock Information
- Founded
- RARE 2010
- BTU 2016
- Country
- RARE United States
- BTU United States
- Employees
- RARE N/A
- BTU N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- BTU Coal Mining
- Sector
- RARE Health Care
- BTU Energy
- Exchange
- RARE Nasdaq
- BTU Nasdaq
- Market Cap
- RARE 3.2B
- BTU 3.5B
- IPO Year
- RARE 2014
- BTU N/A
- Fundamental
- Price
- RARE $33.00
- BTU $29.12
- Analyst Decision
- RARE Strong Buy
- BTU Strong Buy
- Analyst Count
- RARE 15
- BTU 7
- Target Price
- RARE $87.00
- BTU $26.43
- AVG Volume (30 Days)
- RARE 1.4M
- BTU 4.3M
- Earning Date
- RARE 11-04-2025
- BTU 10-30-2025
- Dividend Yield
- RARE N/A
- BTU 1.02%
- EPS Growth
- RARE N/A
- BTU N/A
- EPS
- RARE N/A
- BTU N/A
- Revenue
- RARE $630,598,000.00
- BTU $3,962,300,000.00
- Revenue This Year
- RARE $19.65
- BTU N/A
- Revenue Next Year
- RARE $23.65
- BTU $17.31
- P/E Ratio
- RARE N/A
- BTU N/A
- Revenue Growth
- RARE 20.63
- BTU N/A
- 52 Week Low
- RARE $25.81
- BTU $9.61
- 52 Week High
- RARE $53.04
- BTU $35.99
- Technical
- Relative Strength Index (RSI)
- RARE 52.70
- BTU 52.06
- Support Level
- RARE $29.36
- BTU $29.04
- Resistance Level
- RARE $35.95
- BTU $31.16
- Average True Range (ATR)
- RARE 1.60
- BTU 1.52
- MACD
- RARE -0.36
- BTU -0.14
- Stochastic Oscillator
- RARE 60.79
- BTU 69.84
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About BTU Peabody Energy Corporation
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan and other regions.